



**Evelyn Law**  
*Singapore*

Dr Evelyn Law is a Senior Consultant and an academic Clinician-Scientist at the National University of Singapore (NUS) who completed her post-doctorate fellowship at Boston Children's Hospital/Harvard Medical School and the Program in Clinical Effectiveness at the Harvard T.H. Chan School of Public Health. She has double board certifications in General Paediatrics and Developmental-Behavioural Paediatrics. Her research interests centre on the influences of family and child factors, including socioeconomic status, parental psychopathology, screen time, and chronic medical conditions, on the neurodevelopmental outcomes of children.

Dr Law is the Principal Investigator (PI) of the Paediatric Brain Health Lab at NUS and the Translational Neuroscience Program of the Singapore Institute for Clinical Sciences (SICS). Her lab uses cognitive neuroscience techniques (e.g., EEG) to examine the biological underpinnings of executive functions deficits related to childhood experiences. She also manages the neurocognitive domains of a number of large birth cohort studies in Singapore (e.g., Growing Up in Singapore Towards healthy Outcomes (GUSTO), Mapping Antenatal Maternal Stress (MAMS), etc). She is the recipient of multiple national grants from the Ministry of Education (MOE) and the National Medical Research Council (NMRC) in Singapore.

**Topic: Neurocognitive Late Effects and Rehabilitation**

This presentation discusses common neurocognitive late effects of children who have undergone treatment (i.e., cranial radiation therapy and chemotherapy) for brain tumours. These late effects include attention, executive function, processing speed, and memory difficulties, which together may contribute to poor academic performance. Paediatric oncology professionals have a role in understanding risk-adapted therapy to balance successes in cancer treatment and preservation of neurocognitive functions. Strategies used in survivorship clinics to prevent and treat adverse sequelae, such as cognitive rehabilitation and pharmacotherapy, are discussed.